Marinomed Biotech AG has received funding from the Austrian Research Promotion Agency (FFG) for the development of a SARS-CoV-2 therapy based on Carragelose.
The project aims to clinically test an inhalation solution with Carragelose as an acute treatment for viral pneumonia caused by SARS-CoV-2 or other respiratory viruses. “A causal therapy directly in the lungs can shorten the duration of the disease and thus hospitalisation for patients suffering from viral pneumonia, reduce the number of patients in intensive care and thus bring enormous benefits for patients and the health system,” explains Eva Prieschl-Grassauer, Chief Scientific Officer of Marinomed, in a statement.
Carragelose developed by Marinomed is one of the very few active ingredients with clinical data from patients who have been infected with previously circulating coronaviruses. In 2014, an analysis of coronavirus infected patients showed that the duration of disease was reduced by more than 3 days in the Carragelose treated group when compared to patients treated with placebo.
Within a year, data should be available clarifying whether the Carragelose inhalation solution is safe and its use in patients is a health improvement compared to a placebo. In the current project, the tolerance of the Carragelose inhalation solution will be evaluated first in healthy volunteers. Subsequently, a proof of concept study in patients with viral pneumonia will be conducted at the Medical University of Vienna. In parallel, existing data on the effectiveness of the product serve as the basis for in-vitro tests that will be carried out together with the Medical University of Vienna in order to establish safety and effectiveness.